Literature DB >> 27100373

Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.

Simon D Brandt1,2, Pierce V Kavanagh3, Geraldine Dowling3, Brian Talbot4, Folker Westphal5, Markus R Meyer6, Hans H Maurer7, Adam L Halberstadt8.   

Abstract

Many N,N-dialkylated tryptamines show psychoactive properties in humans and the number of derivatives involved in multidisciplinary areas of research has grown over the last few decades. Whereas some derivatives form the basis of a range of medicinal products, others are predominantly encountered as recreational drugs, and in some cases, the areas of therapeutic and recreational use can overlap. In recent years, 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT) has appeared as a new psychoactive substance (NPS) and 'research chemical' whereas 4-acetoxy-DALT and the ring-unsubstituted DALT have only been detected very recently. Strategies pursued in the authors' laboratories included the preparation and biological evaluation of previously unreported N,N-diallyltryptamines (DALTs). This report describes the analytical characterization of 17 DALTs. Fifteen DALTs were prepared by a microwave-accelerated Speeter and Anthony procedure following established procedures developed previously in the authors' laboratories. In addition to DALT, the substances included in this study were 2-phenyl-, 4-acetoxy-, 4-hydroxy-, 4,5-ethylenedioxy-, 5-methyl-, 5-methoxy-, 5-methoxy-2-methyl-, 5-ethoxy-, 5-fluoro-, 5-fluoro-2-methyl-, 5-chloro-, 5-bromo-, 5,6-methylenedioxy-, 6-fluoro-, 7-methyl, and 7-ethyl-DALT, respectively. The DALTs were characterized by nuclear magnetic resonance spectroscopy (NMR), gas chromatography (GC) quadrupole and ion trap (EI/CI) mass spectrometry (MS), low and high mass accuracy MS/MS, photodiode array detection, and GC solid-state infrared analysis, respectively. A comprehensive collection of spectral data was obtained that are provided to research communities who face the challenge of encountering newly emerging substances where analytical data are not available. These data are also relevant to researchers who might wish to explore the clinical and non-clinical uses of these substances.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  DALT; chemistry; forensic; new psychoactive substances; tryptamines

Mesh:

Substances:

Year:  2016        PMID: 27100373      PMCID: PMC5412731          DOI: 10.1002/dta.1974

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  47 in total

1.  Response of cluster headache to psilocybin and LSD.

Authors:  R Andrew Sewell; John H Halpern; Harrison G Pope
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

2.  [Analytical data of designated substances (Shitei-Yakubutsu) controlled by the Pharmaceutical Affairs Law in Japan, part I: GC-MS and LC-MS].

Authors:  Ruri Kikura-Hanajiri; Maiko Kawamura; Nahoko Uchiyama; Jun Ogata; Hiroyuki Kamakura; Kazuhiro Saisho; Yukihiro Goda
Journal:  Yakugaku Zasshi       Date:  2008-06       Impact factor: 0.302

3.  Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS.

Authors:  Julian A Michely; Andreas G Helfer; Simon D Brandt; Markus R Meyer; Hans H Maurer
Journal:  Anal Bioanal Chem       Date:  2015-08-22       Impact factor: 4.142

4.  Application of a portable near infrared spectrometer for presumptive identification of psychoactive drugs.

Authors:  Kenji Tsujikawa; Tadashi Yamamuro; Kenji Kuwayama; Tatsuyuki Kanamori; Yuko T Iwata; Kazuna Miyamoto; Fumiyo Kasuya; Hiroyuki Inoue
Journal:  Forensic Sci Int       Date:  2014-06-27       Impact factor: 2.395

5.  Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.

Authors:  Michael P Bogenschutz; Alyssa A Forcehimes; Jessica A Pommy; Claire E Wilcox; P C R Barbosa; Rick J Strassman
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

6.  Microwave-accelerated preparation and analytical characterization of 5-ethoxy-N,N-dialkyl-[α,α,β,β-H(4) ]- and [α,α,β,β-D(4) ]-tryptamines.

Authors:  Ruchanok Tearavarich; Viwat Hahnvajanawong; Nicola Dempster; Paul F Daley; Nicholas V Cozzi; Simon D Brandt
Journal:  Drug Test Anal       Date:  2010-12-29       Impact factor: 3.345

Review 7.  The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): a brief review.

Authors:  John M Corkery; Emma Durkin; Simon Elliott; Fabrizio Schifano; A Hamid Ghodse
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-06-07       Impact factor: 5.067

8.  AMT (3-(2-aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole): an analytical challenge and implications for forensic analysis.

Authors:  Simon P Elliott; Simon D Brandt; Sally Freeman; Roland P Archer
Journal:  Drug Test Anal       Date:  2012-10-05       Impact factor: 3.345

Review 9.  Psychedelics and schizophrenia.

Authors:  Javier González-Maeso; Stuart C Sealfon
Journal:  Trends Neurosci       Date:  2009-03-05       Impact factor: 13.837

10.  In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes.

Authors:  Ryouichi Nonaka; Fumiko Nagai; Akio Ogata; Kanako Satoh
Journal:  Biol Pharm Bull       Date:  2007-12       Impact factor: 2.233

View more
  3 in total

Review 1.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

2.  Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs.

Authors:  Landon M Klein; Nicholas V Cozzi; Paul F Daley; Simon D Brandt; Adam L Halberstadt
Journal:  Neuropharmacology       Date:  2018-02-27       Impact factor: 5.250

Review 3.  Toxicology and Analysis of Psychoactive Tryptamines.

Authors:  Sara Malaca; Alfredo Fabrizio Lo Faro; Alice Tamborra; Simona Pichini; Francesco Paolo Busardò; Marilyn A Huestis
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.